Consistently, a six-month randomized, double-blind trial enrolling 148 RA patients showed that individuals with partial responses to methotrexate had clinical improvement after combination therapy with an FDA-approved BCRP inhibitor cyclosporine and methotrexate (47). Here, ABCG2 is linked to rheumatoid arthritis.